Farestaie - Instituto de Análisis

informes
rss Canales Rss Indicaciones previas a pacientes para realizar un análisis. Déjenos su Curriculum

Resultados en línea

Si desea consultar el resultado de su análisis on-line, por favor ingrese en su correspondiente sección.

Informes Multimedia H1N1 - Creando un lugar de trabajo seguro y saludable (Inglés)

Novel H1N1 Flu – Creating a Safe and Healthy Workplace


 

May 20, 2009

 [Announcer] This podcast is presented by the Centers for Disease Control and Prevention. CDC – safer, healthier people.


CDC understands that businesses are concerned about the health and safety of their workers and worksites during this outbreak of novel H1N1 flu. This podcast answers many of the questions we’ve received from the business community and will provide your organization with information on resources and tools to effectively respond to the outbreak.


Novel H1N1 is a new influenza virus causing illness in people. The virus was first detected in people in the United States in April 2009; other countries have also reported people sick with the new virus. CDC expects that more cases, hospitalizations, and deaths from this outbreak will occur over the coming days and weeks.

Businesses are essential partners in protecting the public’s health and safety during this outbreak. The health of employees during an outbreak such as novel H1N1 influenza plays a critical role in the continued operations of a business. The workforce, like the public, needs clear, concise, consistent information.
H1N1 flu is a completely new disease that isn’t comparable to the seasonal flu we see each year. One of the differences is that H1N1 flu is attacking healthy teens and adults. With seasonal flu, the very young and the very old are at greatest risk because their immune systems are less effective than those of healthy adults.
It’s difficult to make accurate predictions on the length of time it may take for the novel H1N1 flu to run its course in the U.S. Past outbreaks have had different durations and affected different percentages of the population in different ways. Outbreaks of new influenza viruses usually last much longer than seasonal flu, and often come in waves. The health impact in terms of severity of each wave has also varied.
Here are some ways to protect employees and worksites:
Sick employees should stay home and not come to work. People who have the flu can spread it to others and the flu virus can spread easily when people are close together. If someone is sick with novel H1N1 flu, they’ll probably have symptoms similar to those of seasonal flu, including fever, cough, sore throat, runny or stuffy nose, body aches, headache, chills, and fatigue. A significant number of people have also reported diarrhea and vomiting.
Tell employees you don’t want them coming to work sick so they don’t worry about losing their job. Let them know their job is safe if they need to care for someone who is sick or are sick themselves. CDC recommends that people who are sick with novel H1N1 flu stay home for seven days after the onset of illness or at least 24 hours after symptoms have subsided, whichever is longer.


To stay healthy or to stop the spread of the virus, remind your employees to do these four things:


1. Cover their nose and mouth with a tissue when they cough or sneeze and then throw the tissue in the trash.
2. Wash their hands often with soap and water, especially after coughing or sneezing, or use an alcohol-based hand cleaner if soap and water aren’t available.
3. Avoid touching their eyes, nose, or mouth to prevent spreading germs.
4. Try to avoid close contact with sick people.


In order to ensure business continuity, develop a plan to protect your employees and maintain operations during this H1N1 flu outbreak. Companies that provide critical infrastructure services, such as power and telecommunications, have a special responsibility to plan for continued operation in a crisis, including consideration for significant absenteeism. Having a contingency plan is essential.
There are no special precautions for workers who handle or deliver packages, other than practicing good hand hygiene. If soap and water aren’t available to these employees, make sure they have a supply of alcohol-based hand cleaner. Instruct them to use it after each contact with customers, including after sharing a pen with customers.


Although the current H1N1 flu virus is new and scientists are still studying it, studies on other forms of flu viruses have shown that influenza virus can survive on environmental surfaces, such as books, countertops, door knobs, and money, and can infect a person for up to eight hours after being deposited on the surface. It’s important to note that in the transportation and shipping industry, banking institutions, and retail businesses - where money and goods move daily - workers have not shown an increase in infection rates during periods of seasonal influenza. To prevent the spread of the virus, it’s important to keep surfaces, especially commonly touched surfaces, such as work stations, countertops, and bathroom surfaces, clean by wiping them down with a household disinfectant, according to label directions.
Employees who need to travel for business can protect themselves by doing a few simple things. All travelers should wash their hands often with soap and water or use an alcohol-based hand cleaner. Travelers may also want to bring alcohol-based sanitizing wipes that can be used to clean hard surfaces near their seat on the airplane, such as seat arms, seatbelt, fold-down tray, and overhead bins.


For more information on how to stay healthy during travel and any updates on CDC travel notices, please visit CDC’s Travelers’ Health website at www.cdc.gov/travel.
For help in preparing your business for the novel H1N1 flu, visit www.cdc.gov/h1n1flu/business
where you’ll find resources, tools, and information for businesses OR call 1-800-CDC-INFO, that’s 1-800-232-4636.


[Announcer] For the most accurate health information, visit www.cdc.gov or call 1-800-CDC-INFO, 24/7.

Podcast- Archivos de sonido con opinion de expertos
Marcadores Bioquímicos en Cardiología
Predicting Heart Attack Risk
Proyecto Jupiter Proteina C Reactiva (Inglés)
Marcador de accidente cerebro-vascular (ACV)
Evaluating Stroke Biomarkers (Inglés)
Gripe H1N1 (Gripe porcina)
Información CDC Gripe Porcina
Qué puedo hacer para protegerme a mi y a mi familia del virus H1N1? (en ingles)
Videos 68º Congreso Argentino de Bioquímica - ABA - 2009
Acto inaugural. Conferencia Plenaria de Apertura.
Reconocimiento a Raquel Osatinsky
Marcadores de estrés oxidativo: ¿Teoría o práctica? 1º parte
Marcadores de estrés oxidativo: ¿Teoría o práctica? 2º parte
Acto de reconocimiento a profesionales
Acto Inaugural. Apertura. Reconocimiento a la Dra. Raquel Osatinsky
Médicos y bioquímicos en busca de consenso para un valor estimado del filtrado glomerular. Su importancia en la atención primaria.
Médicos y bioquímicos en busca de consenso para un valor estimado del filtrado glomerular. Su importancia en la atención primaria - 1º Parte
Médicos y bioquímicos en busca de consenso para un valor estimado del filtrado glomerular. Su importancia en la atención primaria - 2º Parte
Diagnóstico de las crioglobulinemias: Indicaciones e interpretación clínica
Nefrotoxicidad de las crioglobulinas. • Asociación entre hepatitis C y producción de crioglobulinas (1º parte)
Asociación entre hepatitis C y producción de crioglobulinas (2º parte) .• Laboratorio clínico en el estudio de las crioglobulinemias (1º parte).
Videos Congreso IFCC Fortaleza 2008
Conferencia Inaugural
The Ubiquitin Proteolytic System: From Basic Mechanisms through Human Diseases and onto Drug Targeting. (1º parte) (Inglés)
Understanding the T helper response against HIV and CD4+ T-cell-inducing HIV vaccines. (Inglés)
The Ubiquitin Proteolytic System: From Basic Mechanisms through Human Diseases and onto Drug Targeting. (2º parte) (Inglés)
Medicina de Laboratorio Basada en la Evidencia
What is EBLM and how to apply it. (Inglés)
Screening and EBLM: is there a sufficient case for PSA testing? (Inglés)
EBM in cardiac medicine. A case based approach.
Diabetes
Presentación disertantes (10 min) - Biological markers to asses glycaemic control in Diabetes Mellitus (1º parte) (Inglés)
Biological markers to asses glycaemic control in Diabetes Mellitus (2º parte) (Inglés)
Post-translational modifications of proteins in Diabetes (Inglés)
Diabetes and prediabetes: Laboratory update and new diagnostic perspectives (1º parte) (Inglés)
Diabetes and prediabetes: Laboratory update and new diagnostic perspectives (2º parte) (Inglés)
Marcadores Bioquímicos en Cardiología
Gene-environment interactions in cardiovascular diseases (1º parte) (Inglés)
Gene-environment interactions in cardiovascular diseases (2º parte) (Inglés)
Marcadores Bioquímicos en Población Anciana
The clinical application of serum proteomic profile in elderly population (1º parte) (Inglés)
The clinical application of serum proteomic profile in elderly population (2º parte) (Inglés)
Frequency of anemia in elderly population attending for LEPACUEM in 2007 (Inglés)
Metabolic syndrome as risk factor to severe oxidative stress in elderly (Inglés)
Biologia Molecular
Epigenic and genetic profiling in colorectal cancer (Inglés)
SNP analysis and DNA Sequencing based on Molecular Charges.(1º parte) (Inglés)
SNP analysis and DNA Sequencing based on Molecular Charges. (2º parte) (Inglés)
Molecular diagnostic testing in oncology: Clinical utility of mutation detection in cancer prognosis and treatment prediction. (1º parte) (Inglés)
Molecular diagnostic testing in oncology: Clinical utility of mutation detection in cancer prognosis and treatment prediction. (2º parte) (Inglés)
Association between capn10 gene polymorphism and polycystic ovary syndrome in southern chilean women. (Inglés)
Progress in molecular diagnostics of syndromic Hirschsprung diseases and other neurocristopathies. (Inglés)
Aspecto nutricional en el laboratorio de medicina
Laboratory assessment of nutritional status – Where is the evidence? (1º parte) (Inglés)
Laboratory assessment of nutritional status – Where is the evidence? (2º parte) (Inglés)
Obesity laboratory-from bench to bedside. (1º parte) (Inglés)
Obesity laboratory-from bench to bedside. (2º parte) (Inglés)
Detection and possible physiological significance of a CEHC, an urinary metabolite of vitamin E. (Inglés)
Impact of the nutritional status on paf-ah activity and cardiovascular risk biomarkers in adolescents. (Inglés)
Proteómica
Plasma protein biomarker discovery and the peptide atlas. (Inglés)
Understanding the Human proteome. (Inglés)
A Human protein atlas.(Inglés)
Proteomics and clinical chemistry. (Inglés)
Phosphorilation predictors application as analytical model to the muscular condition. (Inglés)
Fully automated multi-analytical measurement of circulating cytokines and cytokine related markers on evidence biochip arrays. (Inglés)
Inmunología clínica
New developments in allergy diagnostics: From IgE to cellular testing. (Inglés)
Diagnostic value of screening and differential testing for antinuclear antibodies. (Inglés)
Chemokine and Chemokine receptors: New inflammatory markers on the horizon. (Inglés)
Inverse relationship between paraoxonase level and symptoms of asthma.(Inglés)
Laboratorio Médico y Osteoporosis
Biochemical markers on bone turnovers Diagnostics for Clinical practice. (Inglés)
Assessment of bone turnover marker plots. (1º parte) (Inglés)
Assessment of bone turnover marker plots. (2º parte) Inglés)
Osteoprogeterim and receptor activator of NF-KB, Novel biomarkers of bone remodeling. (Inglés)
Evaluation of the direct immunoassay eclia 25-OH-D3-Vitamin on Roche Modular E 170-Analizer. (Inglés)
Hormonal contraceptives, bone turnover and risk of osteoporosis. (Inglés)
The effect of partial hepactomy on bone metabolism in rats. (Inglés)
Nuevas tendencias en el laboratorio clínico
From la bon a chip to a lab-in-a cell. (Inglés)
High throughput single cell cultivation and analysis platform. (Inglés)
Marcadores cardíacos: presente y futuro
Emerging markers on acute coronary syndrome: beyond the troponins. (Inglés)
The value of markers in nonischemic heart diseases. (Inglés)
Detection of transient myocardical ischemia using a highly sensitive, single molecule, troponine I assay. (1º parte) (Inglés)
Detection of transient myocardical ischemia using a highly sensitive, single molecule, troponine I assay. (2º parte) (Inglés)
Impact of assay related issues in B-type natriuretic peptide quantification. (Inglés)
Clinical applications of B-type natriuretic peptide testing. (Inglés)
Pentraxina-3 levels ion patients with coronary artery disease in a sample of Brazilian population. (Inglés)
Farmacogenética y el laboratorio clínico
Pharmacogenetics testing for warfarin anticoagulation. (Inglés)
Germline pharmacogenomics in the treatment of breast cancer. (Inglés)
Pharmacogenetics in psychiatry: an update. (Inglés)
Pharmacogenetics in transplantation medicine. (Inglés)
Metabolic abnormalities among female patients with squizophrenia following traetment with second generation antipsychotic are associated with abcb1 genetic polimorphisms. (Inglés)
Diagnóstico molecular de enfermedades infecciosas
Molecular methodes applied to Hepatitis C diagnosis and monitoring. (1º parte) (Inglés)
Molecular methodes applied to Hepatitis C diagnosis and monitoring. (2º parte) (Inglés)
Innovation on the molecular diagnosis of leishmaniosis. (Inglés)
Mutation of toll-like receptor 2 in a lepromatous leprosy patient. (Inglés)
Aumento de la espectrometría de masas ¿caída del inmunoanálisis?
Technological developments in mass spectrometry towards multiplexing and high throughput analysis. (1º parte) (Inglés)
Technological developments in mass spectrometry towards multiplexing and high throughput analysis. (2º parte) (Inglés)
Rise of mass spectrometry-fall of immunoassay? Point of view of an immunoassay manufacturer. (Inglés)
Rise of mass spectrometry-fall of immunoassay? Point of view of an immunoassay manufacturer. (Inglés)
Rise of mass spectrometry-fall of immunoassay? Point of view of the clinical laboratory. (Inglés)
Measurement of 25-hydroxyl vitamin D in blood by liquid chromatography tandem mass spectrometry and comparison to a radioimmunoassay method. (Inglés)
Determination of serum testosterone by liquid chromatography-isotope dilution tandem mass spectrometry. (Inglés)
Laboratorio clínico y manejo de pacientes: ¿cómo se relacionan?
Strategic and financial planning: Critical for the clinical laboratory. (Inglés)
Staffing and privatization of clinical laboratories: two challenges for the next decade. (1º parte) (Inglés)
Staffing and privatization of clinical laboratories: two challenges for the next decade. (2º parte) (Inglés)
Minimizing errors from test ordering to result reporting. (Inglés)
Integrated pathways: the role of the clinical laboratory. (Inglés)
Patterns of thyroid disorders among the neplase patients attending referral health care centre. (Inglés)
Reflective testing: podsitive effect on patient management as judged by general practitioners. (Inglés)
Información de Actualidad
Gripe Porcina
Instructivo uso de Barbijos
Instructivo lavado de manos
H1N1 Influenza (Gripe porcina)
Gripe H1N1 y Drogas Antivirales
Laboratorio clínico en el estudio de las crioglobulinemias. 2º parte
Información para niños: Lo que puedes hacer para que no te dé influenza (Español)
LifeCell

Primer banco de células madre de cordón umbilical del interior

Creado para la tranquilidad de los padres y la seguridad de sus hijos.
Rivadavia 3331 | Constitución 4773 | Avellaneda 1286 1 Piso
Tel/Fax: 0223 410-4820 al 27 o 475-3855 al 58 | 7600 Mar del Plata | Argentina
©2004-2012 Fares Taie Instituto de Análisis
Osmosis